[./productpagepag.html]
[./indexpag.html]
[./support_pagepag.html]
[./contactpagepag.html]
Copyright © 2005 - MRC-Holland
[./indexpag.html]
Home
-
[./productpagepag.html]
Products
-
[./support_pagepag.html]
Support
-
[./article_pagepag.html]
Articles
-
[./contactpagepag.html]
contact
SALSA P027 Uveal Melanoma MLPA Kit
[http://www.geneclinics.org/profiles/hht/details.html]
Lot 0608: Several probes have been replaced by other probes in the same chromosomal regions as compared to previous lots. As a result, the version number has changed to B1. Uveal melanoma is the most common primary intraocular malignancy. In the United States, over a 25-year period (1973-1997) 2493 cases of uveal melanoma were found, representing 2.9% of all recorded cases of melanoma. Most cases (97.8%) occurred in the white population. There was a significant variation of incidence between genders (males, 4.9; females, 3.7). There was no significant variation of incidence by the geographic location of the registry. The mean age-adjusted incidence of uveal melanoma in the United States (4.3 per million) was similar to that reported from European countries. The age-adjusted incidence rate of uveal melanoma had remained stable for over the 25 years (Singh, A. D.; Topham, A: Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology 110: 956-961, 2003). Recent research suggests that uveal melanomas with monosomy 3 (50-60% of all uveal melanomas) represent a distinct pathological entity as compared to uveal melanomas with normal disomy 3. Chromosome 6 aberrations probably constitute a second entry point in the process of carcinogenesis, while gains in 8q seem to appear later in the natural history of uveal melanomas - due to their higher frequency in larger tumors. This P027 Uveal Melanoma probemix contains several probes on chromosomes 1p, 3, 6p and 8q (MYC region). In addition, it contains several reference probes on chromosomes 5, 7, 12, 14, 18, 19 and 21, which are not known to be frequently amplified or deleted in uveal melanoma. This SALSA MLPA kit is designed to detect gains and/or loses of the aforementioned regions. Heterozygote deletions of probe recognition sequences should give a 35-50% reduced relative peak area of the amplification product of that probe. However, mutations and/or polymorphisms very close to the probe ligation site may also result in a reduced relative peak area. Therefore, apparent deletions detected by a single probe always require confirmation by other methods. Please note that most defects in these genes are expected to be small (point) mutations, most of which will not be detected by this MLPA test
Full mix description (pdf)
Current Lot Number.: Lot 0608
IMPORTANT NOTICE: MLPA kits are sold by MRC-Holland for research purposes and to demonstrate the possibilities of the MLPA technique. This kit is not CE/FDA certified for use in diagnostic procedures. Salsa MLPA kits are supplied with all necessary buffers and enzymes. Purchase of the Salsa MLPA test kits includes a limited license to use these products for research purposes. The use of this MLPA kit requires a thermocycler with heated lid and sequence type electrophoresis equipment. Different fluorescent PCR primers are available. The MLPA technique has been first described in Nucleic Acid Research 30, e57 (2002)
References
[./order_infopag.html]
[./products_prenatal_and_postnatalpag.html]
[./products_hereditary_cancer_researchpag.html]
[./products_various_syndromespag.html]
[./products_tumor_characterisationpag.html]
[./products_mrna_analysispag.html]
[./products_methylation_specificpag.html]
[./products_otherpag.html]
[./products_pharmacogeneticspag.html]
[./mlpapricelistpag.html]
[Web Creator] [LMSOFT]